<DOC>
	<DOCNO>NCT00451321</DOCNO>
	<brief_summary>The purpose study optimize several multi-dose regimen otelixizumab , determine high biologically active dose , evaluate biomarkers surrogate efficacy , evaluate effect multi-dose regimen otelixizumab standard safety efficacy parameter .</brief_summary>
	<brief_title>TRX4 Monoclonal Antibody Type 1 Diabetes ( T1 DM )</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<criteria>Adults 12 45 year old good general health Confirmed diagnosis insulin require type 1 diabetes mellitus good glycemic control Measurable Cpeptide level Females must pregnant lactate willing practice contraception No prior malignancy , nonmelanoma skin cancer Body Mass Index ( BMI ) &gt; 32 screening</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>type 1 diabetes mellitus</keyword>
	<keyword>diabetes mellitus type 1</keyword>
	<keyword>type 1 diabetes</keyword>
	<keyword>diabetes mellitus</keyword>
	<keyword>diabetes</keyword>
</DOC>